Ultragenyx Pharmaceutical (RARE) Asset Utilization Ratio (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Asset Utilization Ratio data on file, last reported at 0.47 in Q1 2026.

• Asset Utilization Ratio for Q1 2026 came in at 0.47, up 12.95% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.47 (up 12.95% YoY), and the FY2025 annual result was 0.44, up 18.56% from the prior year.
• Asset Utilization Ratio retreated to 0.47 in Q1 2026 per RARE's latest filing, from 0.49 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.5 in Q3 2025 and troughed at 0.23 in Q1 2022.
• A 5-year average of 0.34 and a median of 0.32 in 2023 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2022 and 2025: Asset Utilization Ratio dropped 2.61% in 2022, then soared 52.47% in 2025.
• A 5-year view of Asset Utilization Ratio shows it stood at 0.23 in 2022, then jumped by 38.48% to 0.32 in 2023, then increased by 15.79% to 0.37 in 2024, then soared by 34.2% to 0.49 in 2025, then decreased by 4.16% to 0.47 in 2026.
• Business Quant data shows RARE's Asset Utilization Ratio at 0.47 in Q1 2026, 0.49 in Q4 2025, and 0.5 in Q3 2025.